Empfohlen
Empfohlen
Weitere ähnliche Inhalte
Was ist angesagt?
Was ist angesagt? (20)
Ähnlich wie Life Raft Group: A New Model for Cancer Research
Ähnlich wie Life Raft Group: A New Model for Cancer Research (20)
Mehr von TRAIN Central Station
Mehr von TRAIN Central Station (15)
Kürzlich hochgeladen
Kürzlich hochgeladen (20)
Life Raft Group: A New Model for Cancer Research
- 1. LIFE RAFT GROUP A New Model for Cancer Research December 2009
- 2. THE LIFE RAFT GROUP Dedicated to finding a cure for Gastrointestinal Stromal Tumors (GIST)
- 7. Potential Therapies Genotype Current Initial Therapy Potential Initial Therapies Imatinib-Resistance KIT exon 11 Imatinib Masitinib Nilotinib Sorafenib Imatinib + PI3K inhibitor Sunitinib (poor) Sorafenib HSP90 inhibitors KIT exon 9 Standard dose imatinib High dose imatinib Sunitinib Sunitinib HSP90 inhibitors Wild-type Imatinib (poor response) Sunitinib Nilotinib Masitinib IGF1R inhibitors Sunitinib Nilotinib Masitinib IGF1R inhibitors PDGFRA D842V (exon 18) Imatinib (very poor) Dasatinib HSP90 inhibitors Dasatinib HSP90 inhibitors
- 8. KIT Gleevec - Sunitinib - Dasatinib-Sorafenib-Nilotinib PKC412-AMG706-MP470-HSP-90 inhibitors (indirect) PI3K BEZ235 - GDC0941 SF1125-XL765 AKT Perifosine mTOR RAD001 - CCI779 AP-23573-Rapamycin PKC-θ RAS R115777-SCH66336 RAF-1 Sorafenib MEK MAPK BCL-2 Gentasense BCL-X L BAD Src/Fyn/Lyn Dasatinib Survive Proliferate VEGFR (antiangiogenesis) Sunitinib-AMG706-PKC412 Sorafenib-Avastin Progress in understanding GIST Targets and Treatments HSP90 IPI504 - BIIB021 AUY922-STA9090 SNX5422 Other Receptors IGF1R (wild-type) AXL HDAC LBH589-SAHA STAT3 Survive-grow
- 9. Gleevec Resistance: Median Time to Progression is 24 Months
- 10. ABOUT THE LIFE RAFT GROUP
- 11. Our Mission LRG Member & GIST Patient Andrea Fuller SURVIVAL
- 16. Networking Dr. David Epstein, head of Novartis Oncology worldwide Dr. James Watson, Nobel Prize Winner Ted Kennedy and Dan Vasella, CEO of Novartis ACOR Pres., Gilles Frydman and Dana-Farber Sarcoma Chief, George Demetri
- 18. CHALLENGES FOR CANCER RESEARCH
- 19. What’s wrong with this? ASCO 2007: “Major Research Advances in Cancer Treatment” Treatment Improvement Avastin Doubled Progression Free Survival Sorafenib 44% longer life Radiotherapy 53% longer life Improvement OUTCOME FOR PATIENTS 5.4 months to 10.2 months 4.8 months 7.9 months to 10.7 months 2.8 months 17 weeks to 29 weeks 3 months
- 21. The LRG Response
- 32. Our Collaborators: LRG Research Team Dr. Brian Rubin, TheCleveland Clinic Dr. Jonathan Fletcher, Brigham & Women’s Hospital Dr. Chris Corless, Oregon Health & Science University Dr. Michael Heinrich, Oregon Health & Science University Dr. Cristina Antonescu, Memorial Sloan Kettering Cancer Center Dr. Anette Duensing, University of Pittsburgh Cancer Center Dr. Matt van de Rijn, Stanford University Dr. Maria Debiec-Rychter, University of Leeuven, Belgium Dr. Sebastian Bauer, University of Essen, Germany Dr. Peter Besmer, Memorial Sloan Kettering Cancer Center
- 39. For More Information Norman J. Scherzer Executive Director 973-837-9092 [email_address] www.liferaftgroup.org
Hinweis der Redaktion
- PKC-theta – important target in GIST, but no drug yet (1-2009) RAS may be a potential target for NF-1 type GISTs
- We will discuss mutational and plasma testing further in a general session Sunday. There are also free plasma level testing kits available for patients.
- We will discuss mutational and plasma testing further in a general session Sunday. There are also free plasma level testing kits available for patients.
- We will discuss mutational and plasma testing further in a general session Sunday. There are also free plasma level testing kits available for patients.
- We will discuss mutational and plasma testing further in a general session Sunday. There are also free plasma level testing kits available for patients.